045 – Gilead PrEP Revenue in JEOPARDY!

Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN.

I mention a short-term trade idea but remember to do your own due diligence and do not consider this investment advice.


Leave a Reply

%d bloggers like this: